Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Contemporary Management of HIV 2021: Modifying ART in Virologically Suppressed Patients

Review guidelines and key data on modifying ART in virologically suppressed patients, including switching ART to decrease pill burden and avoid comorbidities, switching to a long-acting injectable, and simplifying ART in the context of known multidrug resistance.
David Malebranche, MD, MPH
Released: August 25, 2021

In this episode, David Malebranche, MD, MPH, discusses modifying ART in virologically suppressed patients, including switching ART in a patient with daily pill fatigue, switching ART to avoid comorbidities and simplifying ART in the context of known multidrug resistance. The overview will include analyses from:

  • The ATLAS and FLAIR studies in which long-acting intramuscular CAB + RPV was initiated after initial virologic suppression with oral therapy
  • D:A:D study data that found cumulative use of RTV-boosted DRV, but not RTV-boosted ATV, was independently associated with a small but progressively increasing risk of CVD events
  • The SWORD-1 and -2 evaluating the switch to DTG + RPV vs continuation of baseline ART in virologically suppressed adults
  • The TANGO study that compared switching to DTG/3TC vs continuing a TAF-based 3-drug regimen
  • The DAWNING study that showed favorable outcomes for treatment-experienced patients switched to DTG containing regimens with an M184V mutation, whether the regimen contained emtricitabine or lamivudine or not
  • Study 380-4030 that showed noninferiority in maintenance of viral suppression when switching to BIC/FTC/TAF from DTG + FTC/(TAF or TDF)
  • BRAAVE 2020 that evaluated the impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWH

In addition, Dr. Malebranche reviews current recommendations by the DHHS regarding considerations when switching regimens in virologically suppressed patients and switching regimens in patients with viral suppression and drug resistance.

Information on this Educational Activity


David Malebranche, MD, MPH

Internal Medicine Physician
HIV/Sexual Health Specialist
AIDS Healthcare Foundation (AHF) Medical Clinic
Atlanta, Georgia

David Malebranche, MD, MPH, has disclosed that he has received consulting fees from Gilead Sciences and ViiV and fees for non-CME services from Gilead Sciences.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director
person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 20, 2023 Expired: January 19, 2024

Dr Eric Florence discusses clinic adaptations to promote successful integration of long-acting injectables for HIV in this commentary from Clinical Care Options (CCO)

Eric Florence, MD, PhD Released: January 17, 2023

Listen to expert faculty discuss strategies to promote ART safety and tolerability in aging patients and populations with cardiometabolic toxicities, from Clinical Care Options (CCO)

Marta Boffito, MD, PhD, FRCP Jens D. Lundgren, MD, DMSc Released: January 17, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings